It was Mr. Bertinotti who raised that.
What I can say is that the regulations have to be improved because it's very costly to develop new vaccines and health products. That puts a major damper on Canadian biosecurity, especially if we're trying to reduce the number of human health products we use, particularly class 1 products. The challenge is to come up with new products.
I'll let the other witnesses address that point.